

141. (Currently amended) The method of claim 139~~140~~, wherein said exogenous DNA encodes an immunomodulator.
142. (Original) The method of claim 141, wherein said immunomodulator is interferon β .
- 143-194. (Withdrawn)

REMARKS


I. Status of the Claims

1-194 are pending in the application. Claims 133-135 and 137-142 have been examined, as claims 1-132, 136 and 143-194 stand withdrawn pursuant to a restriction requirement and election of species. Claims 140 and 141 are now amended in order to address claim dependency errors resulting from amendments offered in the response filed on May 27, 2003.

II. Conclusion

In light of the foregoing, applicants respectfully submit that all claims are in condition for allowance, and an early notification to that effect is earnestly solicited. Should the examiner have any questions regarding this response, a telephone call to the undersigned is invited.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 5, 2003